Merck
OrganizationHeard in 159 episodes across 55 shows since Sep 2025
Merck & Co., known as MSD outside the United States and Canada, is a global pharmaceutical company that develops and markets prescription medicines, vaccines, and biologic therapies.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Merck per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Sep 25 | 0.04‰ | 2 |
| Sep 28 | 0.04‰ | 2 |
| Sep 30 | 0.04‰ | 1 |
| Oct 1 | 0.08‰ | 4 |
| Oct 5 | 0.06‰ | 2 |
| Oct 6 | 0.08‰ | 2 |
| Oct 9 | 0.07‰ | 4 |
| Oct 10 | 0.08‰ | 1 |
| Oct 13 | 0.06‰ | 2 |
| Oct 14 | 0.08‰ | 2 |
| Oct 15 | 0.11‰ | 4 |
| Oct 16 | 0.09‰ | 2 |
| Oct 18 | 0.10‰ | 1 |
| Oct 19 | 0.10‰ | 1 |
| Oct 20 | 0.09‰ | 1 |
| Oct 22 | 0.06‰ | 2 |
| Oct 23 | 0.09‰ | 6 |
| Oct 25 | 0.09‰ | 1 |
| Oct 26 | 0.12‰ | 4 |
| Oct 27 | 0.13‰ | 3 |
| Oct 29 | 0.14‰ | 2 |
| Oct 30 | 0.11‰ | 3 |
| Oct 31 | 0.13‰ | 2 |
| Nov 1 | 0.13‰ | 1 |
| Nov 2 | 0.13‰ | 4 |
| Nov 3 | 0.12‰ | 2 |
| Nov 9 | 0.02‰ | 1 |
| Nov 10 | 0.02‰ | 1 |
| Nov 11 | 0.02‰ | 1 |
| Nov 12 | 0.04‰ | 1 |
Email alert
Email me when Merck comes up on a podcast
One email a week at most, with the new episodes that mention Merck. Free, no account needed, unsubscribe in one click.
What experts have said about Merck
19 statements · 16 positive · 3 mixed
Merck remains a good long-term holding.
“100% a good hold.”
Open the episode · NVIDIA Risk, Anthropic IPO Test, and Texas Roadhouse RallyListen at 9:16
Merck is attractive for investors bullish on the cancer-vaccine prospects.
“Merck is actually somewhat compelling here, I think, if you're actually bullish on the prospects.”
Open the episode · Tech Tumbles In Market Sell-Off… And Moderna’s Meltdown After Data Leak 10/22/26Listen at 28:48
Merck is currently performing very well
“I think that they are doing incredibly well.”
Open the episode · Mad Money w/ Jim Cramer 10/9/26Listen at 31:19
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
159 episodes featuring Merck, newest first
- Nov 12, 2026
AI infrastructure faces its profitability testMad Money w/ Jim CramerNov 12, 2026 - Nov 11, 2026
Ro bets healthcare’s future on patient demand and softwareInvest Like the Best with Patrick O'ShaughnessyNov 11, 2026 - Nov 10, 2026
Anthropic IPO could reset the AI investment tradeMad Money w/ Jim CramerNov 10, 2026 - Nov 9, 2026
Biotech investors weigh obesity, RAS drugs and Moderna catalystsBreaking BiotechNov 9, 2026 - Nov 6, 2026
Calley Means says lobbying derailed the MAHA health agendaThe Joe Rogan ExperienceNov 6, 2026 - Nov 3, 2026
Nasdaq rebound tests market breadth as election risk risesStock Market Today With IBDNov 3, 2026